We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy (CERVANTES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04989647
Recruitment Status : Recruiting
First Posted : August 4, 2021
Last Update Posted : July 26, 2022
Sponsor:
Information provided by (Responsible Party):
David Cibula, General University Hospital, Prague

Brief Summary:
The objective of the trial is to evaluate if adjuvant (chemo)radiation is associated with a disease-free survival benefit after radical surgery in patients with intermediate risk cervical cancer. The primary endpoint of the study is the disease-free survival from the day of randomisation. A total of 514 patients are required to achieve 80% power on 5% significance level with non-inferiority margin of 5% to test the difference between the ARMs using Cox proportional hazards model. The maximal tolerated margin for non-inferiority in 2-year DFS is 5% (including expected drop-out rate of 10%).

Condition or disease Intervention/treatment Phase
Cervical Cancer Radiation: No adjuvant therapy Radiation: Adjuvant radiotherapy Phase 3

Detailed Description:

The role of adjuvant (chemo)radiotherapy in intermediate risk (IR) cervical cancer patients is controversial, supported by single randomised GOG 92 study performed more than 20 years ago. Intermediate-risk group is defined as lymph node negative but with a combination of negative prognostic factors (tumour size >2 cm, lymphovascular space invasion, deep stromal invasion >2/3). Recent retrospective studies showed excellent local control in intermediate risk group patients after radical surgery with no additional adjuvant treatment.

CERVANTES trial is designed to bring level A evidence on the role of adjuvant treatment in IR patients in an international, prospective, randomised study. Patients will be registered into the trial before surgery and randomised after the final pathology report has been received into ARM A, with no additional treatment, and ARM B, receiving adjuvant (chemo)radiotherapy. Quality assurance program will be in place for both, radical surgery and adjuvant treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 514 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An International Randomised Trial of Radical Surgery Followed by Adjuvant (Chemo)Radiation Versus no Further Treatment in Patients With Early-stage, Intermediate-risk Cervical Cancer Patients
Actual Study Start Date : June 10, 2022
Estimated Primary Completion Date : December 2029
Estimated Study Completion Date : December 2032

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Experimental: A: Surgery only

Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*. No further treatment will be administered.

*PLND can be avoided in patients with tumours < 4cm

Radiation: No adjuvant therapy
Patients will not receive any type of adjuvant therapy.

Experimental: B: Surgery + radiothrerapy

Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*, followed by adjuvant treatment.

*PLND can be avoided in patients with tumours < 4cm

Radiation: Adjuvant radiotherapy
Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).




Primary Outcome Measures :
  1. Disease-free survival [ Time Frame: Analysed 3 years after randomization of the last patient. ]
    Calculated as an interval from the day of randomisation until diagnosis of recurrence: (a) unequivocal finding on imaging by subjective radiological assessment; b) suspicious recurrence on imaging either confirmed by biopsy or supported by other signs (disease progression on imaging or progression of symptoms); (c) physical examination supported by clinical evidence (i.e., symptoms or progression); or (d) death caused by disease or death of unknown cause.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Analysed 6 years after randomization of the last patient. ]
  2. Pelvic disease-free survival [ Time Frame: Analysed 3 years after randomization of the last patient. ]
  3. Health-related quality of life based questionnaire [ Time Frame: Analysed 3 years after randomization of the last patient. ]
    The analysis will be made based on EORTC validated questionnaires and developed qualitative CERVANTES questionnaire.

  4. Treatment-related adverse events based on Common Terminology Criteria for Adverse Events v5.0 [ Time Frame: Analysed 3 years after randomization of the last patient. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically confirmed invasive cervical cancer
  • FIGO IB1-IIA
  • Squamous cell cancer or HPV-related adenocarcinoma
  • Presence of tumour-related risk factors as follows:

    1. tumour ≥4 cm OR
    2. tumour>2 cm <4 cm AND lymphovascular space invasion OR
    3. tumour >2 cm <4 cm AND tumour free distance <3 mm OR
    4. tumour >2 cm <4 cm AND deep stromal invasion (>2/3)
  • No evidence of suspicious pelvic lymph nodes or distant metastases on imaging (by radiological subjective assessment before surgery and negative pelvic LN on final pathology)
  • ECOG performance status 0-1
  • Deemed suitable and fit for radical surgery followed by adjuvant radiotherapy
  • Negative pregnancy test (if applicable)
  • Negative HIV test (only performed in high-risk countries or patients who have moved from those countries within the past 10 years)

Exclusion Criteria:

  • Adenosquamous cancer or adenocarcinoma unusual type (non-HPV related - such as: mucinous, clear cell, mesonephric) or other rare tumour types (those not listed in the inclusion criteria)
  • Inconclusive primary site of disease
  • Unequivocally positive lymph node by imaging (by radiological subjective assessment)
  • FIGO <IB1 / >IIA
  • Previous pelvic malignancy
  • History of second primary cancer outside pelvis if ≤ 3 years complete clinical remission (CCR)
  • Previous pelvic radiotherapy
  • Neoadjuvant chemotherapy prior surgical treatment
  • Low likelihood of patient compliance to the follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04989647


Contacts
Layout table for location contacts
Contact: Martina Borcinova, PhD +420224969298 martina.borcinova@cervantes-trial.com
Contact: Trial Office +420224967432 trial.office@cervantes-trial.com

Locations
Layout table for location information
Czechia
General University Hospital in Prague Recruiting
Prague, Czechia, 12000
Contact: Martina Borcinova    +420224969298    martina.borcinova@cervantes-trial.com   
Sponsors and Collaborators
The Central and Eastern European Gynecologic Oncology Group
Investigators
Layout table for investigator information
Principal Investigator: David Cibula, prof. General University Hospital in Prague, Czech Republic
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: David Cibula, prof. David Cibula, MD, PhD, General University Hospital, Prague
ClinicalTrials.gov Identifier: NCT04989647    
Other Study ID Numbers: ENGOT-cx16/CEEGOG/CERVANTES
First Posted: August 4, 2021    Key Record Dates
Last Update Posted: July 26, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by David Cibula, General University Hospital, Prague:
intermediate risk cervical cancer
adjuvant radiotherapy
disease free survival
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases